The World's First Hospital: I Build A Palace Of Medicine

May 22.

Lu Chen brought his secretary Tan Xiao to the National Engineering Technology Research Center of Neuromedicine at Yinhe Hospital.

News from the research center.

They have made breakthroughs in the field of Alzheimer's disease drug research and development, and have completed phase III clinical trials.

Lu Chen was very happy about this.

Alzheimer's disease, also known as "senile dementia".

Clinically, it is characterized by comprehensive dementia such as memory impairment, aphasia, apraxia, agnosia, impairment of visuospatial skills, executive dysfunction, and personality and behavior changes.

After the elderly suffer from Alzheimer's disease.

Memory turns to quicksand.

Loved ones become strangers.

The mind is like a child.

The world returns to zero.

Alzheimer's disease is like a "memory eraser" that ruthlessly erases the patient's memory.

According to statistics.

There are 50 million Alzheimer's patients worldwide.

There are about 10 million Alzheimer's patients in China, which is the country with the largest number of patients in the world. 25

If there are new drugs with significant curative effect.

The Alzheimer's disease patients across the country will welcome the gospel!

In the director's office.

Lu Chen and Tan Xiao met Lin Quan, director of the research center.

Lin Quan is nearly sixty years old, but he looks vigorous and vigorous.

Lu Chen asked: "Director Lin, you said that the phase III clinical trial has been completed?"

"That's right!"

Lin Quan nodded, and said slowly: "Before I worked in the National Engineering Technology Research Center of Medical Neuropharmaceuticals, I was studying the pathogenesis of Alzheimer's disease, and I have conducted experiments on more than 2,700 mice.

After joining the company, my team finally determined its pathogenesis after supporting each other, complementing each other, and improving each other.

Alzheimer's disease is not just a neurodegenerative disease of the brain.

It is an immune system disease that is caused by an imbalance of intestinal flora, which leads to systemic disorders.

Therefore, we used marine brown algae extract as raw material to prepare low molecular acid oligosaccharide compounds.

Then, from the 5,000 low-molecular acid oligosaccharide compounds, we screened layer by layer, and finally found one of them.

After various research and development.

We finally developed Milky Way Nectar Capsules!

At present, Yinhe Manlu has completed subclinical trials.

We conducted safety, tolerance, placebo-controlled, double-blind and other clinical trials on 2,000 Alzheimer's patients.

The drug can effectively treat mild, moderate and severe Alzheimer's disease and improve the cognitive function of patients.

compared to placebo.

The new drug reduced the comprehensive index of the patient's condition by 32%.

This is statistically significant!"

The voice fell.

Lu Chen's eyes lit up.

There are only six anti-Alzheimer's drugs on the market.

Tacrine was launched in 1993.

Donepezil launched in 1996.

Rivastigmine was launched in 2000.

Galantamine launched in 2001.

Memantine hydrochloride launched in 2003.

The memantine/donepezil compound preparation launched in 2014.

These six drugs can only treat symptoms and cannot delay the progression of Alzheimer's disease.

But Milky Way Nectar has a significant effect on improving patients' cognition!

Alzheimer's patients saved!

On the side, secretary Tan Xiao said curiously: "Director Lin, the road to drug research and development is long.

The laboratory confirms the discovery of the target.

A series of preclinical studies will take two to three years.

Relevant preclinical trials will take another two to three years.

It will take three to seven years to conduct Phase I trials, Phase II trials, and dish trials.

However, the National Engineering Technology Research Center for Medical Neuropharmaceuticals completed all the steps of new drug research and development in just 13 months after its establishment.

Does it comply with national drug research and development regulations?"

"Of course it does!"

Lin Quan explained with a smile: "Our National Engineering Technology Research Center for Medical Neuropharmaceuticals discovered targets very quickly when it was established.

It took only one month from the discovery of the target to the confirmation, to the synthesis of the lead compound, and finally to the discovery and development of the drug.

In the pre-clinical test stage, we evaluated the pharmacological and toxicological effects of the drug, carried out the production process, quality control, stability research, animal tests and other links, and it took only 2 months

Phase I clinical trial took 3 months, Phase II clinical trial took 3 months, and subclinical trial took 6 months, completely exceeding the national minimum clinical trial regulations

In subclinical trials, the emergence of the Galaxy supercomputer has helped us solve many problems.

In the end, Yinhe Manlu Capsules completed all the drug research and development links!"

Hearing this, Tan Xiao nodded in admiration.

It is indeed the National Engineering Technology Research Center!

Lu Chen smiled slightly.

There are four basic conditions for the rapid development of drugs.

First, the 600 scientific research institutions of Yinhe Hospital are blessed with academic and scientific research halos. In the field of scientific research, "if there is God's help"

Second, Professor Lin Quan and other researchers are top experts in various fields in China.

Third, Yinhe Hospital invests in scientific research institutions regardless of cost.

Fourth, in January this year, the Galaxy supercomputer was put into use.

Yinhe Manlu Capsule was successfully developed.

Four conditions are indispensable!

Lin Quan said: "Dean Lu, the research and development of Yinhe Ganlu Capsules has been completed.

We will immediately submit various application materials to the National Center for Drug Evaluation for review.

Compared with drug development, new drug approval takes a lot of time.

Dean, we hope to get this drug on the market as soon as possible.

So that more Alzheimer's patients can alleviate their symptoms, instead of waiting for two or three years, three or four years..."

According to regulations.

The Drug Approval Center should complete the review of the new drug application within 537 days of 6 months.

But a new drug application material can be as many as 100,000 pages, or even more.

Many drug applications are not standardized.

Therefore, the review cannot be completed within half a year.

If it is slow, it may take three to seven years to pass the approval of new drugs......

If the approval is not passed, there will be no new drug certificate.

Without a new drug certificate, the drug cannot be marketed.

If it cannot be sold on the market, patients with Alzheimer's disease cannot take Yinhe Manlu Capsules.

This is what Lin Quan does not want to see!

"Director Lin, don't worry!"

Lu Chen said with a smile: "Now the state encourages drug innovation and expedites review, and new drugs for the treatment of serious or life-threatening diseases can make decisions within 60 days at the earliest.

Yinhe Manlu Capsules have obvious therapeutic effect on Alzheimer's disease patients.

This new drug will definitely be able to go through the fast-track review channel.

In addition, our Galaxy Pharmaceutical Group opened on March 12, and it has been more than two months now.

The group has the top pharmaceutical equipment, but has not yet produced any kind of drug.

We also very much hope that the new drug will be approved!"

hear this.

Lin Quan smiled and nodded.

Dean Lu is the richest man in the country of Xia, and he is very well connected.

With his guarantee.

The speed of approval of new drugs may be faster.

Only through approval.

Only domestic Alzheimer's patients can buy new drugs as soon as possible. .